Epidemiology, treatment and outcomes of nosocomial pneumonia due to Gram-negative bacteria Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007
Prevalence of atypical bacterial pathogens in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013
The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006
The etiological agents of community-acquired pneumonia in our hospital Source: Eur Respir J 2006; 28: Suppl. 50, 735s Year: 2006
Aerosolized colistin in critically ill patients for the treatment of ventilator-associated pneumonia, due to multidrug-resistant gram-negative bacteria Source: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006
Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007
Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007
Preventing community-acquired pneumonia Source: International Congress 2019 – Respiratory infections: prevention is better than cure Year: 2019
MRSA as a cause of community-acquired pneumonia Source: Eur Respir J 2009; 34: 1013-1014 Year: 2009
Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia Source: Eur Respir J 2009; 33: 521 Year: 2009
Multidrug-resistant bacteria in community-acquired pneumonia Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice Year: 2017
Risk factors for drug-resistant pathogens in patients with hospital-acquired and ventilator-associated pneumonia Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017
Update on preventing and managing hospital-acquired and ventilatory-associated pneumonia Source: International Congress 2019 – State of the art session: Respiratory infections Year: 2019
Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis Year: 2017
Nosocomial superinfection is one of the principal cause of mortality in severe community-acquired pneumonia Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008
Multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009
Antibiotics and new guidelines for the treatment of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=175 Year: 2004
Potential antibiotic resistant pathogens in community-acquired pneumonia: playing it safe is anything but Source: Eur Respir J, 54 (1) 1900870; 10.1183/13993003.00870-2019 Year: 2019
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010